Despite promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from managed care entities. Such organizations are frequently creating limitations to reimbursement, like significant expense restrictions and approval processes that restrict us… Read More